Challenges in measuring and valuing productivity costs, and their relevance in mood disorders

ClinicoEconomics and Outcomes Research

Volumn 5, Issue 1, 2013, Pages 565-573

  Lensberg, Benedikte R ^a   Drummond, Michael F ^b   Danchenko, Natalya ^c   Despiégel, Nicolas ^d   François, Clément ^c  

^a OPTUM   (United States)

^b UNIVERSITY OF YORK   (United Kingdom)

^c Lundbeck   (France)

^d OptumInsight   (France)

Author keywords

Absenteeism; Biomedical; Cost benefit analysis; Mood disorders; Presenteeism; Productivity loss; Technology assessment

Indexed keywords

ABSENTEEISM; ANXIETY DISORDER; BIPOLAR DISORDER; COST BENEFIT ANALYSIS; DEPRESSION; ECONOMIC EVALUATION; GOVERNMENT; HEALTH INSURANCE; HUMAN; INCOME; JOB PERFORMANCE; MOOD DISORDER; PRODUCTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; RETIREMENT; REVIEW;

EID: 84887852074     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S44866     Document Type: Review

References (42)

1. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. 2008. Available from: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed October 25, 2012.
2. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies. 2006. Available from: http://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf. Accessed October 25, 2012.
3. Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3). 2008. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbacguidelines-index. Accessed July 18, 2013.
4. College voor Zorgverzekeringen. [Guidelines for pharmacoeconomic research]. Updated version. 2006. Available from: http://www.cvz.nl/zorgpakket/cfhagenda/commissie/farmaco-economisch+onderzoek/farmaco-economisch+onderzoek.html. Accessed October 25, 2012. Dutch.
5. Tandvårds-och Läkemedelsförmånsverket. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2). 2003. Available from: http://www.tlv.se/Upload/English/ENG-lfnar-2003-2.pdf. Accessed October 25, 2012.
6. Koopmanschap MA, Rutten FF, van Ineveld BM, van RL. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14:171-189.
7. Franke LC, Ament AJ, van de Laar MA, Boonen A, Severens JL. Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol. 2009;27:S118-S123.
8. Sobocki P, Ekman M, Agren H, et al. Resource use and costs associated with patients treated for depression in primary care. Eur J Health Econ. 2007;8:67-76.
9. Munoz MCL, Medina-Mora ME, Borges G, Zambrano J. Social cost of mental disorders: disability and work days lost. Results from the Mexican survey of psychiatric epidemiology. Salud Mental. 2007;30: 4-11.
10. Wang PS, Beck AL, Berglund P, et al. Effects of major depression on moment-in-time work performance. Am J Psychiatry. 2004;161: 1885-1891.
11. Schultz AB, Chen CY, Edington DW. The cost and impact of health conditions on presenteeism to employers: a review of the literature. Pharmacoeconomics. 2009;27:365-378.
12. Stewart WF, Ricci JA, Chee E, Hahn SR, Morganstein D. Cost of lost productive work time among US workers with depression. JAMA. 2003;289:3135-3144.
13. Kessler RC, Akiskal HS, Ames M, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of US workers. Am J Psychiatry. 2006;163:1561-1568.
14. Sculpher M. The role and estimation of productivity costs in economic evaluation. In: Drummond M, McGuire A, editors. Economic Evaluation in Health Care: Merging Theory with Practice. Oxford, UK: Oxford University Press; 2001.
15. Lofland JH, Pizzi L, Frick KD. A review of health-related workplace productivity loss instruments. Pharmacoeconomics. 2004;22:165-184.
16. Brooks A, Hagen SE, Sathyanarayanan S, Schultz AB, Edington DW. Presenteeism: critical issues. J Occup Environ Med. 2010;52:1055-1067.
17. Kessler RC, Ames M, Hymel PA, et al. Using the World Health Organization Health and Work Performance Questionnaire (HPQ) to evaluate the indirect workplace costs of illness. J Occup Environ Med. 2004;46:S23-S37.
18. Stewart WF, Ricci JA, Leotta C, Chee E. Validation of the work and health interview. Pharmacoeconomics. 2004;22:1127-1140.
19. Lerner D, Amick BC III, Lee JC, et al. Relationship of employee-reported work limitations to work productivity. Med Care. 2003;41:649-659.
20. Despiegel N, Danchenko N, Francois C, Lensberg B, Drummond MF. The use and performance of productivity scales to evaluate presenteeism in mood disorders. Value Health. 2012;15:1148-1161.
21. Drummond MF, Knapp MR, Burns TP, Shadwell P. Issues in the design of studies for the economic evaluation of new atypical antipsychotics: the ESTO study. J Ment Health Policy Econ. 1998;1:15-22.
22. Burton WN, Morrison A, Wertheimer AI. Pharmaceuticals and worker productivity loss: a critical review of the literature. J Occup Environ Med. 2003;45:610-621.
23. Backhouse ME, Wonder M, Hornby E, Kilburg A, Drummond M, Mayer FK. Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study. Value Health. 2011;14:608-615.
24. Birnbaum H. Friction-cost method as an alternative to the human-capital approach in calculating indirect costs. Pharmacoeconomics. 2005;23:103-104.
25. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics. 1998;13:1-7.
26. Goeree R, O'Brien BJ, Blackhouse G, Agro K, Goering P. The valuation of productivity costs due to premature mortality: a comparison of the human-capital and friction-cost methods for schizophrenia. Can J Psychiatry. 1999;44:455-463.
27. Brouwer WB, Koopmanschap MA, Rutten FF. Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion. Health Econ. 1997;6:511-514.
28. Dagenais S, Caro J, Haldeman S. A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J. 2008;8:8-20.
29. Wieser S, Horisberger B, Schmidhauser S, et al. Cost of low back pain in Switzerland in 2005. Eur J Health Econ. 2011;12:455-467.
30. Nicholson S, Pauly MV, Polsky D, Sharda C, Szrek H, Berger ML. Measuring the effects of work loss on productivity with team production. Health Econ. 2006;15:111-123.
31. Pauly MV, Nicholson S, Polsky D, Berger ML, Sharda C. Valuing reductions in on-the-job illness: 'presenteeism' from managerial and economic perspectives. Health Econ. 2008;17:469-485.
32. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
33. van Asselt AD, Dirksen CD, Arntz A, Severens JL. Difficulties in calculating productivity costs: work disability associated with borderline personality disorder. Value Health. 2008;11:637-644.
34. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford, UK: Oxford University Press; 2005.
35. Brouwer WB, Meerding WJ, Lamers LM, Severens JL. The relationship between productivity and health-related QOL: an exploration. Pharmacoeconomics. 2005;23:209-218.
36. Lamers LM, Meerding WJ, Severens JL, Brouwer WB. The relationship between productivity and health-related quality of life: an empirical exploration in persons with low back pain. Qual Life Res. 2005;14: 805-813.
37. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1253-1258.
38. Tilling C, Krol M, Tsuchiya A, Brazier J, van Exel J, Brouwer W. The impact of losses in income due to ill health: does the EQ-5D reflect lost earnings? Health Economics and Decision Science Discussion Paper Series No 09/04. 2011.
39. Kaitelidou D, Ziroyanis PN, Maniadakis N, Liaropoulos LL. Economic evaluation of hemodialysis: implications for technology assessment in Greece. Int J Technol Assess Health Care. 2005;21:40-46.
40. Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med. 1992;34:1005-1010.
41. Lopez-Bastida J, Serrano-Aguilar P, Duque-Gonzalez B. Socioeconomic costs of cardiovascular disease and cancer in the Canary Islands (Spain) in 1998. Gac Sanit. 2003;17:210-217. Spanish.
42. Oliva J, Lobo F, Lopez-Bastida J, Zozaya N, Romay R. Indirect costs of cervical and breast cancers in Spain. Eur J Health Econ. 2005;6:309-313.